WHO ICTRP trial
A study to test the safety/efficacy of Brivaracetam (BRV) used as adjunctive…
EUCTR2019-001205-25-Outside-EU/EEA · EU Clinical Trials Register
Key facts
| Trial ID | EUCTR2019-001205-25-Outside-EU/EEA |
|---|---|
| Public title | A study to test the safety/efficacy of Brivaracetam (BRV) used as adjunctive treatment in subjects >=16 years of age with partial seizures with or without secondary generalization |
| Scientific title | An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization |
| Primary sponsor | UCB Biopharma SRL |
| Registry | EU Clinical Trials Register |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | China;Japan |
| Conditions | Epilepsy (partial seizures with or without secondary generalization);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] |
| Interventions | Trade Name: Briviact Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Brivaracetam CAS Number: 357336-20-0 Current Sponsor code: BRV Other descriptive name: ucb 34714 Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Apr 25, 2025 |
| Secondary IDs | EP0085;NCT03250377 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: